PharmacoEconomics & Outcomes News 497 - 25 Feb 2006
Market growth predicted forseveral drug classes
Recent market forecasts have predicted high growthin the sales of antirheumatics, antihypertensives, sleepdisorder therapies and influenza vaccines.
The global market for rheumatoid arthritis (RA) showsno signs of decline, valued at $US4.14 billion in 2004.1
The recent launch of etanercept [Enbrel] and theanticipated launch of adalimumab [Humira] for thetreatment of RA is expected to push the market forbiological agents above that of traditional DMARDs by2010 in Japan.
Angiotensin II receptor antagonists and noveltherapies are expected to be the major players in theantihypertensive market, which has growth predicted inexcess of $US50 billion by 2014 in France, Germany,Italy, Japan, Spain the UK and the US.2 However,although the angiotensin II receptor antagonists arecurrently the most frequently prescribed class ofantihypertensive, their value is predicted to flatten after2009 due to the likely availability of generic equivalents.
The market for the treatment of sleep disorders,currently estimated at $US4.3 billion, is forecast to riseto $US6.6 billion by 2012.3 Expansion in this area isexpected due to new indications, novel drugs offeringefficacy whilst minimising adverse events, and agentsbeing developed for the treatment of sleep-wake rhythmdisorders and to improve wakefulness in occupationalsettings.
The demand for influenza virus vaccines is expectedto increase to 370 million doses and expand the marketto a value of $US3.7 billion by 2010 in the seven majormarkets.4 Sales of the vaccine in 2004 accounted forover $US1 billion, an increase of 10% from 2003.1. Research and Markets. The Recent Launch of Enbrel and Forecast Launch of
Humira in the Rheumatoid Arthritis Market is Expected to Push the BiologicClass above Traditional DMARDS by 2010 in Japan. Media Release : 14 Feb2006. Available from: URL: http://www.researchandmarkets.com.
2. Research and Markets. The Antihypertensive Market is Expected to Exceed$50Bn by 2014 across the Seven Major Markets. Media Release : 14 Feb 2006.Available from: URL: http://www.researchandmarkets.com.
3. Piribo Ltd. Piribo: Drug Companies Wake up to Insomniacs; Market forSleeping Disorders Forecast to Triple to $11bn by 2012. Media Release : 13 Feb2006. Available from: URL: http://www.piribo.com.
4. Research and Markets. New Research Forecasts That in the Seven MajorMarkets Demand for Influenza Vaccines Will Expand to 370 Million Doses anda Market Value of $3.7 Billion by 2010. Media Release : 9 Feb 2006. Availablefrom: URL: http://www.researchandmarkets.com.
800996849
1
PharmacoEconomics & Outcomes News 25 Feb 2006 No. 4971173-5503/10/0497-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
